Atropisomerism in Drug Discovery and Development

Let’s Twist Again! Atropisomerism in Drug Discovery and Development

Atropisomerism is defined as conformational chirality originating from restricted rotation around a sigma-bond. Frequently encountered in hindered biaryl or heteroaryl systems, the combination of configurational stability and unique stereochemical architectures has been leveraged in the discovery and development of single atropisomers as both experimental and marketed drugs. In this webinar I will discuss the origin and structural characteristics of atropisomers, their application in drug discovery, and the challenges involved in their clinical development.

This webinar was presented by Dr John Studley, Scientific Update and was kindly sponsored by Axplora

About Axplora:

Created from the merger of Farmabios, Novasep and PharmaZell, Axplora is a leading API manufacturing partner to pharmaceutical and biotechnology companies, supporting them throughout the entire drug lifecycle.  Leveraging its combined expertise and manufacturing capabilities across nine industrial sites, Axplora offers CDMO solutions and specialized technologies to innovators as well as API products.